Xiuning Le, MD, Ph.D., Department of Thoracic-Head and Neck Med Onc, Division of Cancer Medicine MD Anderson speaks about Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION). Link to the Trial:https://clinicaltrials.gov/ct2/show/NCT02864992 Brief Synopsis: The VISION Study is a phase two, single-arm, multi-center, global trial that evaluated the efficacy of tepotinib, a small molecule inhibitor … Continue reading Tepotinib Phase II VISION Trial NSCLC MET [VIDEO]